Advertisement
UK markets closed

  • FTSE 100

    8,275.38
    +44.33 (+0.54%)
     

  • FTSE 250

    20,730.12
    +59.25 (+0.29%)
     

  • AIM

    805.79
    +3.10 (+0.39%)
     

  • GBP/EUR

    1.1742
    -0.0007 (-0.06%)
     

  • GBP/USD

    1.2738
    +0.0006 (+0.05%)
     

  • Bitcoin GBP

    53,122.95
    +23.82 (+0.04%)
     

  • CMC Crypto 200

    1,425.02
    -3.55 (-0.25%)
     

  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     

  • DOW

    38,686.32
    +574.84 (+1.51%)
     

  • CRUDE OIL

    77.18
    -0.73 (-0.94%)
     

  • GOLD FUTURES

    2,347.70
    -18.80 (-0.79%)
     

  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     

  • HANG SENG

    18,079.61
    -150.58 (-0.83%)
     

  • DAX

    18,497.94
    +1.15 (+0.01%)
     

  • CAC 40

    7,992.87
    +14.36 (+0.18%)
     
PROPERTY:

10 bijou homes that are big on style

Size isn’t everything when it comes to buying a home

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

Terns Pharmaceuticals, Inc.
·1-min read
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc.

FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a virtual fireside chat at UBS Obesity Therapeutics Day on Thursday, May 23, 2024 at 1:00 p.m. ET.

A live webcast of the fireside chat will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the event.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com